Despite a century of research, several clinically relevant areas of bilirubin biochemistry remain controversial, poorly understood, or unrecognized. These include: (i) The structure and molecularity of bilirubin under physiological environments such as membranes, brain tissue and when bound to proteins. Related to this is the large number of structurally different bilirubin species that may occur in blood under pathological conditions and their potential effects on measurements of bilirubin and free bilirubin. (ii) The mechanism of phototherapy, the neurotoxicity of the photoisomers produced and their influence on measurements of bilirubin and free bilirubin. (iii) The role of membrane transporters in the passage of unconjugated bilirubin across the placenta, intestine, vascular epithelium, blood-brain barrier, and into the liver. (iv) Biochemical mechanisms of bilirubin toxicity, pharmacologic prevention of kernicterus, the contribution of bilirubin to antioxidant defenses, and the practical value of free bilirubin measurements for identifying infants at most risk of kernicterus.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.siny.2009.10.005 | DOI Listing |
Hepatol Int
January 2025
Department of Hepatobiliary Surgery, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, 350025, China.
Background: Large hepatocellular carcinoma (HCC) is difficult to resect and accompanied by poor outcome. The aim was to evaluate the short-term and long-term outcomes of patients who underwent liver resection for large HCC, eventually drawing prediction models for short-term and long-term outcomes.
Methods: 1710 large HCC patients were recruited and randomly divided into the training (n = 1140) and validation (n = 570) cohorts in a 2:1 ratio.
Int J Health Sci (Qassim)
January 2025
Department of Laboratory, Madinah General Hospital, King Salman bin Abdul Aziz Medical City, Madinah Munnawarah, Saudi Arabia.
Objectives: Vitamin B12 (Cobalamin or Cbl) plays a crucial role in normal human growth and development, as well as in neurological, cardiovascular, and immune systems. Previous studies reported association of high levels of cobalamin with solid cancers, hematological disorders, and liver diseases. Reporting the frequency of comorbid diseases with high serum Vitamin B12 level in patients attending KSAMC at Madinah.
View Article and Find Full Text PDFZhongguo Shi Yan Xue Ye Xue Za Zhi
December 2024
Department of Blood Transfusion, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200127, China.
Objective: To investigate and assess hemolytic transfusion reaction in patient with complex and combined anti-Fy and anti-Jk which so as to provide a safety blood transfusion strategy.
Methods: ABO/Rh blood grouping, antibody screening and identification, and Coombs' tests were performed by the routine serological methods include manual tube and automatic blood group analyzer with matching micro-column gel cards from Diagnostic Grifols and Jiangsu LIBO. The hospital information system and laboratory information system were used to collect dada on patients' blood routine tests, liver and kidney function, coagulation, cardiac function, and other clinical indicators before and after blood transfusion were analyzed and compared in conjunction with the patients' clinical manifestations.
Talanta
December 2024
Department of Physics, Indian Institute of Technology Roorkee, Roorkee, Haridwar, Uttarakhand, 247667, India. Electronic address:
Strategic design and development of nanomaterials-based detection platforms specific to critical biomarkers like bilirubin holds immense promise for revolutionizing early disease detection. Bilirubin (BR) plays a pivotal role as a biomarker for liver function, making accurate and timely detection of BR crucial for diagnosing and monitoring of liver diseases. In this work, we synthesized blue light emitting graphene quantum dots (GQDs) via a single step pyrolysis method, which exhibited excellent photostability and biocompatibility.
View Article and Find Full Text PDFAnticancer Res
January 2025
Department of Surgery, Division of Hepato-Biliary-Pancreatic Surgery, Kobe University Graduate School of Medicine, Kobe, Japan.
Background/aim: Atezolizumab plus bevacizumab (AteBev) is widely used as a first-line treatment for advanced hepatocellular carcinoma (HCC). However, evidence regarding the optimal drug sequence following AteBev treatment is limited. This study aimed to compare the treatment outcomes between tyrosine kinase inhibitors (TKIs) and durvalumab plus tremelimumab (DurTre) following AteBev treatment.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!